Please assess the completion status of the following clinical trial:

Trial Title: Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed non-small cell lung cancer (squamous cell, large cell, adenocarcinoma, or some combination of these), with clinical or pathological stage III or IV, or recurrent disease; and~2. Hemoglobin level at or below 120 g/L; and~3. At least 18 years of age;~Exclusion Criteria:~1. Systemic platinum-based chemotherapy for lung cancer during the previous two months or planned platinum-based chemotherapy within the next three months;~2. Patients previously treated with high dose thoracic radiation (\>10 fractions), or surgery, without objective evidence of disease recurrence;~3. Planned high dose thoracic radiation therapy (\>10 fractions);~4. A clinically active malignancy, other than the underlying lung cancer which is expected to influence QoL;~5. Expected survival of three months or less;~6. ECOG Performance status of 3 or 4 (see Appendix D);~7. Multiple CNS metastasis or a single CNS lesion that does not demonstrate radiographic stability (Screening CT of head required only if symptomatic, no radiographic follow-up of single resected lesions required);~8. Blood transfusions within the last 14 days;~9. Previous use of erythropoietin;~10. Anemia due to factors other than cancer / radiotherapy (e.g. hemolysis or gastrointestinal bleeding);~11. Evidence of untreated folate or vitamin B12 deficiency;~12. History of uncontrolled hypertension or diastolic blood pressure greater than 100 mm Hg;~13. History of seizure disorder;~14. Known hypersensitivity to mammalian cell-derived products, albumin or any component of the study drug;~15. Pregnancy, lactation or parturition within the previous 30 days;~16. Unwillingness or inability to complete the required QoL questionnaires;~17. Mental incompetence, including psychiatric or addictive disorders which would preclude meaningful completion of questionnaires;~18. Geographically inaccessible for treatment or follow-up evaluations;~19. Currently enrolled in an ongoing therapeutic study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).